Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints.

Antimicrobial Agents and Chemotherapy
Maiken Cavling ArendrupDanish Fungaemia Study Group

Abstract

The purpose of this study was to evaluate the performance of caspofungin Etest and the recently revised CLSI breakpoints. A total of 497 blood isolates, of which 496 were wild-type isolates, were included. A total of 65/496 susceptible isolates (13.1%) were misclassified as intermediate (I) or resistant (R). Such misclassifications were most commonly observed for Candida krusei (73.1%) and Candida glabrata (33.1%). The revised breakpoints cannot be safely adopted for these two species.

References

Jun 28, 2006·Antimicrobial Agents and Chemotherapy·Morgan HakkiKieren A Marr
May 1, 2007·The Journal of Antimicrobial Chemotherapy·Marie-Thérèse BaixenchEric Dannaoui
Jan 15, 2008·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·UNKNOWN Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility T
Sep 17, 2008·Antimicrobial Agents and Chemotherapy·Guillermo Garcia-EffronDavid S Perlin
Nov 20, 2009·Journal of Clinical Microbiology·M A PfallerD J Diekema
Apr 28, 2010·Journal of Clinical Microbiology·Christopher D PfeifferBarbara D Alexander
Mar 1, 2011·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·M A PfallerUNKNOWN CLSI Subcommittee for Antifungal Testing
Apr 20, 2011·Antimicrobial Agents and Chemotherapy·Nathan P WiederholdThomas F Patterson
May 6, 2011·Journal of Clinical Microbiology·Marlene Axner-ElingsMaiken Cavling Arendrup
Sep 13, 2011·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·L A Vale-SilvaE Pinto
Sep 20, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M C ArendrupUNKNOWN European committee on antimicrobial susceptibility testing - subcommittee on antifungal susceptibility testing (EUCAST-AFST)

❮ Previous
Next ❯

Citations

Oct 24, 2012·Antimicrobial Agents and Chemotherapy·Rasmus Hare JensenMaiken Cavling Arendrup
Oct 12, 2014·Current Opinion in Infectious Diseases·Maiken C Arendrup, David S Perlin
Feb 14, 2014·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·N BourgeoisL Lachaud
Oct 11, 2014·Future Microbiology·Brunella Posteraro, Maurizio Sanguinetti
Jan 8, 2016·Infectious Disease Clinics of North America·Mohammad T AlbatainehNathan P Wiederhold
Apr 5, 2013·Pharmacotherapy·Gregory A Eschenauer, Peggy L Carver
Apr 14, 2016·Medical Mycology Case Reports·Serisha D NaickerNelesh P Govender
Oct 27, 2015·Jundishapur Journal of Microbiology·Gulgun YenisehirliYunus Bulut
Jan 1, 2014·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M C Arendrup
Mar 13, 2014·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Maiken C ArendrupWilliam W Hope
Apr 24, 2013·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M C ArendrupH C Schønheyder
Oct 16, 2015·Revista Do Instituto De Medicina Tropical De São Paulo·Ana Alastruey-IzquierdoJuan L Rodriguez-Tudela
Aug 18, 2018·Journal of Fungi·Ronen Ben-Ami
Jun 1, 2017·Antimicrobial Agents and Chemotherapy·Maria AignerCornelia Lass-Flörl
Jul 30, 2014·Antimicrobial Agents and Chemotherapy·M LacknerG S de Hoog
Sep 2, 2015·Antimicrobial Agents and Chemotherapy·A ForastieroE Mellado
Apr 2, 2014·Antimicrobial Agents and Chemotherapy·Rasmus Hare JensenMaiken Cavling Arendrup
May 12, 2018·Nature Reviews. Disease Primers·Peter G PappasBart Jan Kullberg
Nov 3, 2015·Current Opinion in Infectious Diseases·Ryan K ShieldsCornelius J Clancy
Mar 1, 2019·Journal of Fungi·Maria NoniAthanasios Michos
Oct 12, 2016·Microbiology Spectrum·Sean X Zhang, Nathan P Wiederhold

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.